Advertorial
1Approved indications:
AQUAVAC® PD3 is indicated for the active immunisation of Atlantic salmon to:
• Reduce clinical signs (heart lesions and pancreas lesions), viremia, viral shedding and mortality from infection with pancreas disease (SPDV)
• Reduce mortality from infections with infectious pancreatic necro- sis (IPNV)
• Reduce mortality from infections with furunculosis (Aeromonas salmonicida subsp. salmonicida). FF
About MSD Animal Health Aquaculture
new vaccine for each of the diseases and the additional benefits of a single application vaccine.
Is the new vaccine available now for the forthcoming vaccination season? Yes, the company is now supplying the vaccine to sites throughout the UK and Ireland.
How should producers who vaccinated last season with Compact PD move to AQUAVAC PD3? To support the introduction of AQUAVAC PD3 the UK Aquaculture
team has held several meetings with producers and vets to review their vaccination needs and also to demonstrate the benefits of a one shot vaccine. MSD Animal Health has also produced a series of support and reference materials to aid planning and vaccination.
What additional support is the company able to offer producers? The company has built on the success of the support package, PD
Monitor, to create Aquavac Monitor to UK salmon producers. It has been developed as a strategic tool to assist salmon producers at each key stage of a vaccination programme. As well as advising on site assessments and vaccination routines, Aquavac Monitor includes the confirmation of disease status to establish exposure to disease which is crucial to identifying the success of vaccination programmes. MSD Animal Health has a clear objective to work in strategic part-
nership with our clients. By providing technical advice to producers and by facilitating a continual exchange of health and production data each operation has the opportunity to gain and exploit further im- provement. Additional support is provided through regular bulletins, technical updates and seminars. Producers looking to establish vaccination programmes with AQUA-
VAC PD3 should contact their vet and MSD Animal Health Aquaculture on 03700 6033804.
www.fishfarmer-magazine.com
MSD Animal Health aquaculture business is focused on developing and delivering scienti fi cally proven and economically valuable health soluti ons for the major farmed fi sh species around the world. Our com- pany has been involved in many of the innovati ons that have occurred in the global fi sh farming health area over the past 30 years. This has given us a leadership positi on in the industry. Our business has grown from its pioneering roots with the merger of companies that have been responsible for some of the major scienti fi c breakthroughs in the fi eld of aquaculture health. Notable among these are: the fi rst ever commercial fi sh vaccine (Wildlife 1976), the fi rst European registered fi sh vaccine (AVL 1982), the fi rst IPNv and recombinant IPNv vaccines (Intervet Norbio® 1994), the fi rst oral vaccine and fi rst oral virus vaccine (AVL 1993 and 1999), the fi rst regis- tered fi sh anti bioti c (Coopers 1975), the fi rst ti lapia vaccine, the fi rst oil adjuvanted vaccine in Japan and the fi rst PDv vaccine. In additi on to the long history of
innovati on in vaccine development, MSD Animal Health has developed pharmaceuti cal products suitable for treati ng fi sh desti ned for EU, Japanese and US markets, meeti ng the highest regulatory standards re- quired. These include the parasiti cide SLICE® for the treatment of sea lice. MSD Animal Health is committ ed to the science of healthier fi sh, to meet the challenges the aquaculture industry faces now and in the future. Our focus is to work closely with fi sh farmers, fi sh health experts, veterinary and industry partners to develop and deliver innovati ve, inte- grated fi sh health platf orms to meet the needs of sustainable aquaculture producti on worldwide. In line with this stra-
tegic commitment we have devel-
oped a series of health programmes to support our business around the world. These include an acti ve strain collecti on and identi fi cati on program conducted with our customers farm- ing Tilapia worldwide, The SLICE® sustainability, SLICE® Monitor and Ring Fence programs to support the best practi ce for sea lice treatment using SLICE® in Europe (Norway & UK & Ireland), Canada and Chile. We have introduced PD Monitor in support of the Norvax® Compact PD vaccine now widely used in all at risk farms in Norway, Ireland and Scotland.
MSD Animal Health has two dedi-
cated aquaculture innovati on sites, in Bergen, Norway and in Singapore. These sites have the teams and fa- ciliti es to conduct the work required to develop aquaculture vaccines and other medicines for the future. For more informati on visit: htt p://
aqua.merck-animal-health.com
About MSD Animal Health MSD Animal Health, known as Merck Animal Health in the United States and Canada, is the global animal health business unit of MSD. Through its commitment to the Science of Healthier Animals™, MSD Animal Health off ers veteri- narians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuti cals, vaccines and health management soluti ons and services. MSD Animal Health is dedicated to preserving and improving the health, well-be- ing and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more informati on, visit www.
msd-animal-health.com or connect with us on Linke- dIn.
35
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68